-
1Academic Journal
Συγγραφείς: Yu. G. Belotserkovskaya, A. G. Romanovskikh, I. P. Smirnov, Ю. Г. Белоцерковская, А. Г. Романовских, И. П. Смирнов
Πηγή: Meditsinskiy sovet = Medical Council; № 18 (2022); 122-130 ; Медицинский Совет; № 18 (2022); 122-130 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: порошковый ингалятор, COVID-19 and Asthma, Single Inhaler Maintenance and Reliever Therapy, budesonide/ formoterol, dry powder inhaler, COVID-19 и бронхиальная астма, режим единого ингалятора, будесонид/формотерол
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/7130/6402; To T., Stanojevic S., Moores G., Gershon A.S., Bateman E.D., Cruz A.A., Boulet L.P. Global asthma prevalence in adults: findings from the crosssectional world health survey. BMC Public Health. 2012;(12):204. https://doi.org/10.1186/1471-2458-12-204.; Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.x.; Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0.; Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2.; Cisneros Serrano C., Melero Moreno C., Almonacid Sánchez C., Perpiñá Tordera M., Picado Valles C., Martínez Moragón E. et al. Guidelines for severe uncontrolled asthma. Arch Bronconeumol. 2015;51(5):235–246. https://doi.org/10.1016/j.arbres.2014.12.007.; Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.; Corne J.M., Marshall C., Smith S., Schreiber J., Sanderson G., Holgate S.T., Johnston S.L. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–834. https://doi.org/10.1016/S0140-6736(02)07953-9.; Jackson D.J., Trujillo-Torralbo M.B., del-Rosario J., Bartlett N.W., Edwards M.R., Mallia P. et al. The influence of asthma control on the severity of virus-induced asthma exacerbations. J Allergy Clin Immunol. 2015;136(2):497–500. https://doi.org/10.1016/j.jaci.2015.01.028.; Sykes A., Edwards M.R., Macintyre J., del Rosario A., Bakhsoliani E., Trujillo- Torralbo M.B. et al. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012;129(6):1506–1514. https://doi.org/10.1016/j.jaci.2012.03.044.; Wark P.A., Johnston S.L., Bucchieri F., Powell R., Puddicombe S., Laza- Stanca V. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–947. https://doi.org/10.1084/jem.20041901.; Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A., Bartlett N.W. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026. https://doi.org/10.1038/nm1462.; Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7.; Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. https://doi.org/10.1016/j.jaci.2020.04.006.; Bhatraju P.K., Ghassemieh B.J., Nichols M., Kim R., Jerome K.R., Nalla A.K. COVID-19 in critically ill patients in the Seattle region – case series. N Engl J Med. 2020;(382):2012–2022. https://doi.org/10.1056/NEJMoa2004500.; Garg S., Kim L., Whitaker M., O`Halloran A., Cummings C., Holstein R. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464. https://doi.org/10.15585/mmwr.mm6915e3.; Myers L.C., Parodi S.M., Escobar G.J., Liu V.X. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195–2198. https://doi.org/10.1001/jama.2020.7202.; Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307–314. https://doi.org/10.1016/j.jaci.2020.06.010.; Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. https://doi.org/10.1016/S0140-6736(20)31189-2.; Yang M., Zhang Y., Chen H., Lin J., Zeng J., Xu Z. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection. 2019;47(3):377–385. https://doi.org/10.1007/s15010-018-1229-y.; Yang M., Chen H., Zhang Y., Du Y., Xu Y., Jiang P., Xu Z. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017;29(5):219–226. https://doi.org/10.1080/08958378.2017.1346006.; Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(7):CD002991. https://doi.org/10.1002/14651858.; Contoli M., Pauletti A., Rossi M.R., Spanevellj A., Casolari P., Marcellina A. et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. https://doi.org/10.1183/13993003.00451-2017.; Yamaya M., Nishimura H., Deng X., Sugawara M., Watanabe O., Nomura K. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–168. https://doi.org/10.1016/j.resinv.2019.12.005.; Matsuyama S., Kawase M., Nao N., Shirato K., Ujike M., Kamitani W. et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.03.11.987016. https://doi.org/10.1101/2020.03.11.987016.; Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S. et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20. https://doi.org/10.1128/AAC.00819-20.; Jackson D.J., Busse W.W., Bacharier L.B., Kattan M., O`Connor G.T., Wood R.A. et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. J Allergy Clin Immunol. 2020;146(1):203–206. https://doi.org/10.1016/j.jaci.2020.04.009.; Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19 related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83–90. https://doi.org/10.1164/rccm.202003-0821OC.; Yang J.M., Koh H.Y., Moon S.Y., Yoo I.K., Ha E.K., You S. et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020;146(4):790–798. https://doi.org/10.1016/j.jaci.2020.08.008.; Mahdavinia M., Foster K.J., Jauregui E., Andy-Nweye A.B., Khan S. et al. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract. 2020;8(7):2388–2391. https://doi.org/10.1016/j.jaip.2020.05.006.; Caminati M., Vultaggio A., Matucci A., Vianello A., Vivarelli E., Crisafulli E. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;(176)106261. https://doi.org/10.1016/j.rmed.2020.106261.; Sobieraj D.M., Weeda E.R., Nguyen E., Coleman C.I., White C.M., Lazarus S.C. et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485–1496. https://doi.org/10.1001/jama.2018.2769.; Rogliani P., Ritondo B.L., Ora J., Cazzola M., Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020;56(3):2000625. https://doi.org/10.1183/13993003.00625-2020.; Beasley R., Harrison T., Peterson S., Gustafson P., Hamblin A., Bengtsson T., Fageras M. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma. A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(3):e220615. https://doi.org/10.1001/jamanetworkopen.2022.0615.; Bush A. Severe and Difficult Asthma: Diagnosis and ManagementChallenges for a Low-Resource Environment. Indian J Pediatr. 2022;89(2):156–162. https://doi.org/10.1007/s12098-021-03952-w.; Hodder R. The paradox of adult asthma control: “Who’s in control anyway?” Can Respir J. 2007;14(4):229–234. https://doi.org/10.1155/2007/975134.; Molimard M., Raherison C., Lignot M., Depont F., Abouelfath A., Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16(3):249–254. https://doi.org/10.1089/089426803769017613.; Lavorini F., Magnan A., Dubus J.C., Voshaar T., Corbetta L., Broeders M. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604. https://doi.org/10.1016/j.rmed.2007.11.003.; Dudvarski Ilic A., Zugic V., Zvezdin B., Kopitovic I., Cekerevac I., Cupurdija V. et al. Influence of inhaler technique on asthma and COPD control: a multicenter experience. Int J Chron Obstruct Pulmon Dis. 2016;(11):2509–2517. https://doi.org/10.2147/COPD.S114576.; Игнатова Г.Л., Белевский А.С. Современные способы ингаляционной доставки лекарств при лечении бронхообструктивных заболеваний. Астма и аллергия. 2018;(2):21–28. Режим доступа: https://atmosphere-ph.ru/modules.php?name=Magazines&sop=viewissue&magid=2&issueid=442.; Визель А.А., Белевский А.С., Визель И.Ю. К лечению бронхиальной астмы и хронической обструктивной болезнью легких: идем вперед с проверенными молекулами. Лечебное дело. 2020;(2):59–64. https://doi.org/10.24411/2071-5315-2020-12212.; Emeryk А., Pirożyński M., Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018;86(1):44–52. https://doi.org/10.5603/ARM.2017.0061.
-
2Academic Journal
Πηγή: Качественная клиническая практика, Vol 0, Iss 3, Pp 2-7 (2018)
Θεματικοί όροι: анкетирование, бронхиальная астма, реальная клиническая практика, фармакоэкономика, неинтервенционное исследование, будесонид/формотерол, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441
Περιγραφή αρχείου: electronic resource
Relation: https://www.clinvest.ru/jour/article/view/220; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473
Σύνδεσμος πρόσβασης: https://doaj.org/article/2814fa7192754ed8aae0a211afb694ff
-
3Academic Journal
Συγγραφείς: N. A. Geppe, N. G. Kolosova, S. I. Shatalina
Πηγή: Медицинский совет, Vol 1, Iss 1, Pp 63-67 (2016)
Θεματικοί όροι: budesonide, budesonide/formoterol, будесонид/формотерол, дети, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, children, Medicine, бронхиальная астма, bronchial asthma, inhaled corticosteroids, ингаляционные глюкокортикостероиды, будесонид
Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/11/11
https://doaj.org/article/656b91dbbf104dba8482e96cd1b5d5df
https://cyberleninka.ru/article/n/ratsionalnaya-terapiya-ingalyatsionnymi-kortikosteroidami-pri-bronhialnoy-astme-u-detey
https://www.med-sovet.pro/jour/article/view/11/11
https://cyberleninka.ru/article/n/ratsionalnaya-terapiya-ingalyatsionnymi-kortikosteroidami-pri-bronhialnoy-astme-u-detey/pdf -
4Report
Θεματικοί όροι: SMART therapy, budesonide/formoterol, будесонид/формотерол, Симбикорт Турбухалер, asthma, anti-inflammatory bronchodilator, chronic obstructive pulmonary disease, ингаляционная терапия, inhalation therapy, metered-dose powder inhaler, противовоспалительный бронхолитик, Symbicort Turbuhaler, бронхиальная астма, хроническая обструктивная болезнь легких, дозированный порошковый ингалятор, режим SMART
-
5Academic Journal
Συγγραφείς: Avdeev, S. N., Aisanov, Z. R., Belevskiy, A. S., Emelyanov, А. V., Knyazheskaya, N. P., Kurbacheva, O. M., Leshchenko, I. V., Nenasheva, N. M., Авдеев, С. Н., Айсанов, З. Р., Белевский, А. С., Емельянов, А. В., Княжеская, Н. П., Курбачева, О. М., Лещенко, И. В., Ненашева, Н. М.
Θεματικοί όροι: ASTHMA, INHALED CORTICOSTEROIDS, SHORT-ACTING Β2-AGONISTS, BUDESONIDE/FORMOTEROL FIXED COMBINATION AS NEEDED, SYGMA TRIAL (SYMBICORT® GIVEN AS NEEDED IN MILD ASTHMA), БРОНХИАЛЬНАЯ АСТМА, ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, КОРОТКОДЕЙСТВУЮЩИЕ Β2-АГОНИСТЫ, ФИКСИРОВАННАЯ КОМБИНАЦИЯ БУДЕСОНИД / ФОРМОТЕРОЛ ПО ПОТРЕБНОСТИ, КЛИНИЧЕСКАЯ ПРОГРАММА SYGMA (SYMBICORT® GIVEN AS NEEDED IN MILD ASTHMA)
Περιγραφή αρχείου: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7246
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7246
-
6Academic Journal
Συγγραφείς: Avdeev, S. N., Aisanov, Z. R., Belevskiy, A. S., Kulbaisov, А. М., Kurbacheva, O. M., Leshchenko, I. V., Nenasheva, N. M., Fassakhov, R. S., Авдеев, С. Н., Айсанов, З. Р., Белевский, А. С., Кулбаисов, А. М., Курбачева, О. М., Лещенко, И. В., Ненашева, Н. М., Фассахов, Р. С.
Θεματικοί όροι: MILD ASTHMA, INHALED CORTICOSTEROIDS, SHORT-ACTING Β2-AGONISTS, AS-NEEDED USE OF INHALED CORTICOSTEROID/LONG-ACTING Β2-AGONIST COMBINATION, BUDESONIDE/FORMOTEROL, БРОНХИАЛЬНАЯ АСТМА ЛЕГКОЙ СТЕПЕНИ, ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, КОРОТКОДЕЙСТВУЮЩИЕ БРОНХОДИЛАТАТОРЫ, КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГАЛЯЦИОННЫМИ ГЛЮКОКОРТИКОСТЕРОИДАМИ / ДЛИТЕЛЬНО ДЕЙСТВУЮЩИМИ Β2-АГОНИСТАМИ ПО ТРЕБОВАНИЮ, БУДЕСОНИД / ФОРМОТЕРОЛ
Περιγραφή αρχείου: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7295
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7295
-
7Academic Journal
Συγγραφείς: S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, A. M. Kulbaisov, O. M. Kurbacheva, I. V. Leshchenko, N. M. Nenasheva, R. S. Fassakhov, С. Н. Авдеев, З. Р. Айсанов, А. С. Белевский, А. М. Кулбаисов, О. М. Курбачева, И. В. Лещенко, Н. М. Ненашева, Р. С. Фассахов
Πηγή: PULMONOLOGIYA; Том 28, № 1 (2018); 84-95 ; Пульмонология; Том 28, № 1 (2018); 84-95 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-1
Θεματικοί όροι: будесонид / формотерол, inhaled corticosteroids, short-acting β2-agonists, as-needed use of inhaled corticosteroid/long-acting β2-agonist combination, budesonide/formoterol, ингаляционные глюкокортикостероиды, короткодействующие бронходилататоры, комбинированная терапия ингаляционными глюкокортикостероидами / длительно действующими β2-адреноагонистами по требованию
Περιγραφή αρχείου: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/965/808; Dusser D., Montani D., Chanez P. et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007; 62 (6): 591–604. DOI:10.1111/j.1398-9995.2007.01394.x.; Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; (6): 87–93. DOI:10.18093/0869-0189-2011-0-6-87-93.; Кулбаисов А.М., Полумордвинцева Т.В., Жестков А.В. Фармакотерапия больных бронхиальной астмой: проблемы и возможные пути их решения. 2017. Вестник современной клинической медицины. 2017; 10 (3): 18–23. DOI:10.20969/VSKM.2017.10(3).18-23.; Лещенко И.В., Чирков В.И., Лившиц А.А. Эпидемиология бронхиальной астмы в крупном промышленном регионе. Терапевтический архив. 1998; 70 (12): 41–43.; Bo D., Small M. Disease burden of mild asthma: findings from a cross-sectional real-world survey. Adv. Ther. 2017; 34 (5): 1109–1127. DOI:10.1007/s12325-017-0520-0.; Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report. London: RCP; 2014. Available at: https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills [Accessed 09 January, 2018].; Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 2014; 24: 14009. DOI:10.1038/npjpcrm.2014.9.; Sadatsafavi M., Lynd L., Marra C. et al. Direct health care costs associated with asthma in British Columbia. Can. Respir. J. 2010; 17 (2): 74–80. DOI:10.1155/2010/361071.; Nunes C., Pereira A.M., Morais-Almeida M. Asthma costs and social impact. Asthma Res. Pract. 2017; 3: 1. DOI:10.1186/s40733-016-0029-3.; Российское респираторное общество. Клинические рекомендации: Бронхиальная астма. 2016. Доступно по: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ [Дата обращения: 09.01.18].; Jose, B.P., Camargos, P.A., Cruz Filho, A.A., Correa, R.A. Diagnostic accuracy of respiratory diseases in primary health units. Rev. Assoc. Med. Bras. 2014; 60, 599–612.; Magnoni M.S., Caminati M., Senna G. et al. Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy. Clin. Mol. Allergy. 2015; 13: 26. DOI:10.1186/s12948-015-0032-x.; National Asthma Education and Prevention Program: Expert panel report 3: Guidelines for the diagnosis and management of asthma. Full Report 2007. National Heart, Lung, and Blood Institute; 2007.; Gillis R.M.E., van Litsenburg W., van Balkom R.H. et al. The contribution of an asthma diagnostic consultation service in obtaining an accurate asthma diagnosis for primary care patients: results of a real-life study. NPJ Prim. Care Respir. Med. 2017; 27 (1): 35. DOI:10.1038/s41533-017-0027-9.; From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA), 2017. Available at: http://www.ginasthma.org/ [Accessed 09 January, 2018.]; Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI:10.2147/COPD.S153770.; Loymans R.J., Gemperli A., Cohen J. et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. Br. Med. J. 2014; 348: g3009. DOI:10.1136/bmj.g3009.; Емельянов А.В., Горячкина Л.А., Астафьева Н.Г. и др. Аллергический ринит и бронхиальная астма в реальной клинической практике: результаты Российского многоцентрового исследования. Российский аллергологический журнал. 2012; (1): 29–36.; Ebmeier S., Thayabaran D., Braithwaite I. et al. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet. 2017; 390 (10098): 935–945. DOI:10.1016/S0140-6736(17)31448-4.; Sears M.R., Taylor D.R., Print C.G. et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990; 336 (8728): 1391–1396. DOI:10.1016/0140-6736(90)93098-A.; Gauvreau G.M., Jordana M., Watson R.M. et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am. J. Respir. Crit. Care Med. 1997; 156 (6): 1738–1745. DOI:10.1164/ajrccm.156.6.96-08042.; Aldridge R.E., Hancox R.J., Robin Taylor D. et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. 2000; 161 (5): 1459–1464. DOI:10.1164/ajrccm.161.5.9906052.; Cockcroft D.W., Swystun V.A., Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am. J. Respir. Crit. Care Med. 1995; 152 (5, Pt 1):1485–1489. DOI:10.1164/ajrccm.152.5.7582281.; Cockcroft D.W., O'Byrne P.M., Swystun V.A., Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J. Allergy Clin. Immunol. 1995; 96 (1): 44–49. DOI:10.1016/S0091-6749(95)70031-5.; Hancox R.J., Aldridge R.E., Cowan J.O. et al. Tolerance to beta-agonists during acute bronchoconstriction. Eur. Respir. J. 1999; 14 (2): 283–287.; Haahtela T., Tuomisto L.E., Pietinalho A. et al. A 10 year asthma programme in Finland: major change for the better. Thorax. 2006; 61 (8): 663–670. DOI:10.1136/thx.2005.055699.; Pauwels R.A., Pedersen S., Busse W.W. et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003; 361 (9363): 1071–1076. DOI:10.1016/S0140-6736(03)12891-7.; Reddel H.K., Busse W.W., Pedersen S. et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017; 389 (10065): 157–166. DOI:10.1016/S0140-6736(16)31399-X.; Suissa S., Ernst P., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332–336. DOI:10.1056/NEJM200008033430504.; Gauvreau G.M., Doctor J., Watson R.M. et al. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care Med. 1996; 154 (5): 1267–1271. DOI:10.1164/ajrccm.154.5.8912734.; Gauvreau G.M., Boulet L.P., Postma D.S. et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J. Allergy Clin. Immunol. 2005; 116 (2): 285–2891. DOI:10.1016/j.jaci.2005.05.021.; Lange P., Scharling H., Ulrik C.S., Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax. 2006; 61 (2): 100–104. DOI:10.1136/thx.2004.037978.; Barnes C.B., Ulrik С.S. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir. Care. 2015; 60 (3): 455–468. DOI:10.4187/respcare.03200.; Krishnan J.A., Riekert K.A., McCoy J.V. et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am. J. Respir. Crit. Care Med. 2004; 170 (12): 1281–1285. DOI:10.1164/rccm.200403-409OC.; Piecoro L.T., Potoski M., Talbert J.C., Doherty D.E. Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population. Health Serv. Res. 2001; 36 (2): 357–371.; O’Byrne P.M., Pedersen S., Lamm C.J. et al. Severe exacerbations and decline in lung function in asthma. Am. J. Respir. Crit. Care Med. 2009; 179 (1): 19–24. DOI:10.1164/rccm.200807-1126OC.; O'Byrne P.M., Pedersen S., Schatz M. et al. The poorly explored impact of uncontrolled asthma. Chest. 2013; 143 (2): 511–523. DOI:10.1378/chest.12-0412.; Murphy V.E., Clifton V.L., Gibson P.G. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax. 2006; 61 (2): 169–176. DOI:10.1136/thx.2005.049718.; Boulay M.E., Boulet L.P. Discordance between asthma control clinical, physiological and inflammatory parameters in mild asthma. Respir. Med. 2013; 107 (4): 511–518. DOI:10.1016/j.rmed.2012.12.015.; O’Byrne P.M., Jenkins C., Bateman E.D. The paradoxes of asthma management: time for a new approach? Eur. Respir. J. 2017; 50 (3): 1701103. DOI:10.1183/13993003.01103-2017.; Busse W.W., Pedersen S., Pauwels R.A. et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma. J. Allergy Clin. Immunol. 2008; 121 (5): 1167–1174. DOI:10.1016/j.jaci.2008.02.029.; Lacasse Y., Archibald H., Ernst P., Boulet L.P. Patterns and determinants of compliance with inhaled steroids in adults with asthma. Can. Respir. J. 2005; 12 (4): 211–217.; Papi A., Canonica G.W., Maestrelli P. et al. Rescue use of beclomethasone and albuterol in as a single inhaler for mild asthma. N. Engl. J. Med. 2007; 356 (20): 2040–2052. DOI:10.1056/NEJMoa063861.; Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Принципы выбора терапии для больных легкой бронхиальной астмой. Согласованные рекомендации РААКИ и РРО. Практическая пульмонология. 2017; (1): 82–92.; Rabe K.F., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006; 368 (9537): 744–753. DOI:10.1016/S0140-6736(06)69284-2.; Patel M., Pilcher J., Pritchard A. et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir. Med. 2013; 1 (1): 32–42. DOI:10.1016/S2213-2600(13)70007-9.; Jorup C., Lythgoe D., Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur. Respir. J. 2018; 51 (1): 1701688. DOI:10.1183/13993003.01688-2017.; Bisgaard H., Le Roux P., Bjamer D. et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006; 130 (6): 1733–1743. DOI:10.1378/chest.130.6.1733.; Haahtela T., Tamminen K., Malmberg L.P. et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur. Respir. J. 2006; 28 (4): 748–755. DOI:10.1183/09031936.06.00128005.; Papi A., Marku B., Scichilone N. et al. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. Lancet Respir. Med. 2015; 3 (2): 109–119. DOI:10.1016/S2213-2600(14)70266-8.; O'Byrne P.M., FitzGerald J.M., Zhong N. et al. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials. Trials. 2017; 18 (1): 12–25. DOI:10.1186/s13063-016-1731-4.; Beasley R., Pavord I., Papi A. et al. Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. Eur. Respir. J. 2016; 47 (3): 981–984. DOI:10.1183/13993003.01692-2015.; Fingleton J., Hardy J., Baggott C. et al. Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. BMJ Open Respir. Res. 2017; 4 (1): e000217. DOI:10.1136/bmjresp-2017-000217; https://journal.pulmonology.ru/pulm/article/view/965
-
8Academic Journal
Πηγή: Качественная клиническая практика, Vol 0, Iss 3, Pp 2-7 (2018)
Θεματικοί όροι: анкетирование, бронхиальная астма, реальная клиническая практика, фармакоэкономика, неинтервенционное исследование, будесонид/формотерол, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441
Relation: https://www.clinvest.ru/jour/article/view/220; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473; https://doaj.org/article/2814fa7192754ed8aae0a211afb694ff
Διαθεσιμότητα: https://doaj.org/article/2814fa7192754ed8aae0a211afb694ff
-
9Academic Journal
Συγγραφείς: N. M. Nenasheva
Πηγή: Медицинский совет, Vol 0, Iss 11, Pp 36-41 (2015)
Θεματικοί όροι: пыльцевая бронхиальная астма, будесонид/формотерол, симбикорт, pollen asthma, budesonide/formoterol, symbicort, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/286; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/8465b4d5b0a94268b389ac0c78dc439d
-
10Academic Journal
Συγγραφείς: Наталия Михайловна Ненашева, Оксана Владимировна Себекина
Θεματικοί όροι: бронхиальная астма, режим единого ингалятора (SMART), будесонид/формотерол
Περιγραφή αρχείου: text/html
-
11Academic Journal
Συγγραφείς: N. M. Nenasheva, Н. М. Ненашева
Πηγή: PULMONOLOGIYA; № 6 (2014); 83-93 ; Пульмонология; № 6 (2014); 83-93 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-0-3
Θεματικοί όροι: будесонид / формотерол, GINA 2014, single inhaler strategy, budesonide / formoterol, GINA (2014), режим единого ингалятора
Περιγραφή αρχείου: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/497/481; GINA 2014. www.ginasthma.org; Чучалин А.Г., Айсанов З.Р., Белевский А.С. и др. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. Пульмонология. 2014; 2: 11–32. / Chuchalin A.G., Aysanov Z.R., Belevskiy A.S. et al. Federal guidelines on diagnosis and treatment of bronchial asthma. Pul'monologiya. 2014; 2: 11–32 (in Russian).; Martin R.J., Szefler S.J., King T.S. et al. National Heart, Lung, and Blood Institutes Asthma Clinical Research Center. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J. Allergy Clin. Immunol. 2007; 119 (1): 73–80.; Berry M., Morgan A., Shaw D.E. et al. Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax. 2007; 62: 1043–1049.; Thomson N.C., Chaudhuri R., Livingston E. Asthma and cigarette smoking. Eur. Respir. J. 2004; 24: 822–833.; Holguin F., Bleecker E.R., Busse W.W. et al. Obesity and asthma: an association modified by age of asthma onset. J. Allergy Clin. Immunol. 2011; 127: 1486–1493.; Berthon B., Macdonald-Wicks L., Gibson P., Wood L. Investigation of the association between dietary intake, disease severity and airway inflammation in asthma. Respirology. 2013; 18: 447–454.; Foschino Barbaro M.P., Costa V.R., Resta O. et al. Menopausal asthma: a new biological phenotype? Allergy. 2010; 65: 1306–1312.; Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur. Respir. J. 2002; 19 (1): 182–191.; Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst. Rev. 2010; Apr. 14; (4): CD005533. DOI:10.1002/14651858. CD005533.pub2.; Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.; Инструкция по медицинскому применению препарата Симбикорт Турбухалер 80 / 4,5 мкг и 160 / 4,5 мкг. Регистрационное удостоверение П No 13167/01. (Изменение No 2 от 21.02.13). / Prescription Drug Leaflet for Symbicort Turbuhaler 80 / 4.5 μg and 160 / 4.5 μg. Registration number П No 13167/01 (change N2, 21.02.13) (in Russian).; Moore W.C., Bleecker E.R., Curran-Everett D. et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 2007; 119: 405–413.; Bai T.R., Vonk J.M., Postma D.S., Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur. Respir. J. 2007; 30: 452–456.; Wu A.C., Tantisira K., Li L. et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest. 2011; 140: 100–107.; O'Byrne P.M., Bisgaard H., Godard P.P. et al. Budesonide / formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129–136.; Rabe K.F., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006; 368: 744–753.; Bousquet J., Boulet L.P., Peters M.J. et al. Budesonide / formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol / fluticasone. Respir. Med. 2007; 101: 2437–2446.; Bateman E.D., Harrison T.W., Quirce S. et al. Overall asthma control achieved with budesonide / formoterol maintenance and reliever therapy for patients on different treatment steps. Respir. Res. 2011, 12: 38.; Prazma C.M., Kral K.M., Gul N. et al. Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. Respir. Med. 2010; 104: 780–787.; Reddel H., Jenkins C., Quirce S. et al. Effect of different asthma treatments on risk of cold-related exacerbations. Eur. Respir. J. 2011; 38: 584–593.; Cates C.J., Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013. DOI:10.1002/14651858.CD007313.pub3.; Kew K.M., Karner C., Mindus S.M., Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2013. Dec 16; 12:CD009019.; Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur. Respir. J. 2007; 29 (3): 587–595.; Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2001; 163: 32–36.; Kelly M., O'Connor T., Leigh R. et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J. Allergy Clin. Immunol. 2010; 125: 349–356.; Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J. Asthma. 2005; 42 (9): 715–724.; Toogood J.H., Baskerville J.C., Jennings B. et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J. Allergy Clin. Immunol. 1982; 70 (4): 288–298.; Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; 6: 87–93. / Arkhipov V.V., Grigor'eva E.V., Gavrishina E.V. Asthma control in Russia: results of the multicenter observational study NIKA. Pul'monologiya. 2011; 6: 87–93 (in Russian).; Nanshan Zhong, Jiangtao Lin, Parthiv Mehta et al. Reallife effectiveness of budesonide / formoterol maintenance and reliever therapy in Asthma Patients Across Asia. BMC Pulm. Med. 2013; 13 (22). DOI:10.1186/1471-2466-13-22.; Søes-Petersen U., Kava T., Dahle R. et al. Budesonide / formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted 'real life' setting. Clin. Respir. J. 2011; 5 (3): 173–182.; van der Palen J., Klein J.J., van Herwaarden C.L.A.et al. Multiple inhalers confuse asthma patients. Eur. Respir. J. 1999; 14 (5): 1034–1037.; Sears M., Radner F. Safety of budesonide / formoterol maintenance and reliever therapy in asthma trials. Respir. Med. 2009; 103: 1960–1968.; Scicchitano R., Aalbers R., Ukena D. et al. Efficacy and safety of budesonide / formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr. Med. Res. Opin. 2004; 20: 1403–1418.; Rabe K.F., Pizzichini E., St?llberg B. et al. Budesonide / formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: A randomised, double-blind trial. Chest. 2006; 129: 246–256.; https://journal.pulmonology.ru/pulm/article/view/497
-
12Academic Journal
Πηγή: Практическая пульмонология.
Θεματικοί όροι: 3. Good health, бронхиальная астма, режим единого ингалятора (SMART), будесонид/формотерол
Περιγραφή αρχείου: text/html
-
13Academic Journal
Συγγραφείς: С. Н. Авдеев, Е. В. Григорьева
Πηγή: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 3 (2011); 2-7 ; Качественная клиническая практика; № 3 (2011); 2-7 ; 2618-8473 ; 2588-0519
Θεματικοί όροι: будесонид/формотерол, бронхиальная астма, реальная клиническая практика, фармакоэкономика, неинтервенционное исследование
Περιγραφή αρχείου: application/pdf
Relation: https://www.clinvest.ru/jour/article/view/220/228; Экспертный совет по здравоохранению Комитета Совета Федерации по социальной политике и здравоохранению. Социально-экономическое бремя бронхиальной астмы и хронической обструктивной болезни лёгких в Российской Федерации. – М., 2010. – 15 с.; Здравоохранение в России. Стат. сб./ Росстат. – М., 2009. – 365 с.; Цой А.Н., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическое исследование новой концепции применения Симбикорта у больных бронхиальной астмы. // Пульмонология., 2007.; № 3.: С. 34–40.; Авксентьева М. В., Курбачева О. М. Оценка затрат на лекарственное обеспечение больных бронхиальной астмой при различных схемах поддерживающей терапии. // Атмосфера, Пульмонология и аллергология. 2009.; № 4.: С. 22–26.; GINA, 2009 – Global strategy for asthma management and prevention. (http://www.ginasthma.org/guidelines-gina-report-globalstrategy-for-asthma.html).; Pauwels R.A. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. // N. Engl. J. Med. 1997.; № 337.: Р. 1405–11.; Shrewsbury S. Metaanalysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). // BMJ. 2000.; № 320.; Р. 1368–1373.; Zetterström O., Buhl R., Mellem H. et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone // .Eur. Respir. J. 2001.; № 18.: Р. 262–268.; Huchon G., Magnussen H., Chuchalin A. et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. // Respir. Med. 2009.; Vol. 103. № (1). Р:. 41–9.; Ställberg B., Ekström T., Neij F. et al. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. // Respir. Med. 2008. Vol. ;102. № (10.)Р. :1360–70.; Dahl R., Chuchalin A., Gor D., et al. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma // Respir. Med. 2006.; № 100.: Р. 1152–1162.; Aalbers R., Backer V., Kava T.T. at al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma // .Curr. Med. Res. and Opinion. 2004.; Vol. 20. № (2.): Р. 225–240.; Kuna P., Peters M.J., Manjra A.I., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. // Int. J. Clin. Pract. 2007.; Vol. 61. № (5):. Р. 725–736.; Bousquet J., Boulet L.P., Peters M.J. et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. // Respir. Med. 2007.;Vol. 101. № (12):. Р. 2437–2446.; Vogelmeier C., D'Urzo A., Pauwels R. et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? // Eur. Respir. J. 2005.; № 26.: Р. 819–828.; Ягудина Р.И. с соавт. и др. Оптимизация поддерживающей терапии с использованием фармакоэкономической модели бронхиальной астмы (ОПТИМА). // Фармакоэкономика. 2010.; № 1.: Р. 40–46.; Рудакова А.В. Фармакоэкономические аспекты терапии бронхиальной астмы. // Фармакоэкономика. 2010.; № 1.: Р. 47–52.; Ягудина Р.И. Фармакоэкономический анализ терапии бронхиальной астмы лекарственным средством Фостер. Отчёт. ММА им. И.М. Сеченова 5 июня 2009 г.; Белевский А.С., Авдеев С.Н., Овчаренко С.И., Княжеская Н.П., Цой А.Н. Письмо в редакцию журнала «Consilium Medicum». // Consilium Medicum. 2010.: #№ 3. (Доступно по адресу: http://www.consilium-medicum.com/medicum/article/19486/).; Travers et al. // Resp. Med. 2007.; № 101.: Р. 1313–20.; Bateman E.D., Reddel H.K., Eriksson G. Overall asthma control: The relationship between current control and future risk. // J. All. Clin. Immunol. 2010.; Vol. 125. № (3.): Р. 600–608.; Государственный реестр цен ЖНВЛП. Доступно по адресу: http://grls.rosminzdrav.ru/PriceLims.aspx.; https://www.clinvest.ru/jour/article/view/220
Διαθεσιμότητα: https://www.clinvest.ru/jour/article/view/220
-
14Report
-
15Academic Journal
Συγγραφείς: Зырянов С.К., Дьяков И.Н., Айсанов З.Р.
Πηγή: Terapevticheskii Arkhiv
Θεματικοί όροι: pharmacoeconomics, budget impact analysis, asthma, mild asthma, moderate to severe asthma, budesonide/formoterol, salbutamol, Salmeterol/fluticasone, фармакоэкономика, анализ влияния на бюджет, бронхиальная астма, легкая, среднетяжелая, тяжелая, будесонид/формотерол, сальбутамол, салметерол/флутиказон
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/95649/
